Next-generation sequencing (NGS) of cell-free DNA (cfDNA) obtained from blood samples may improve diagnostic testing in patients with advanced NSCLC, and may also be faster and less expensive compared to standard tissue profiling, ...
Oct 2, 2020
0
1
A growing number of patients with advanced lung cancer could soon be offered a blood test to help to decide the best treatment for them instead of having to get a tumour sample for analysis. New data from the BFAST trial ...
Sep 30, 2019
0
5
Law enforcement officials say they've seized 75,000 vaping cartridges in Anoka County.
Sep 25, 2019
0
4
(HealthDay)—Possible vaping-related breathing problems have led to the hospitalization of 14 teens and young adults in two states. There were 11 cases of severe breathing problems in Wisconsin and three in Illinois, CNN ...
Aug 6, 2019
0
0
The promise and challenges of liquid biopsy, an emerging, noninvasive method for targeted disease diagnosis and detection of cancer biomarkers to enable improved and personalized therapy, is the focus of a new special issue ...
Apr 22, 2019
0
3
Liquid biopsy-based assessment of PIK3CA mutational status served as a better indicator of progression-free survival compared with analysis of tissue biopsy in breast cancer patients enrolled in the phase III clinical trial ...
Dec 6, 2018
0
3
Lecturer and researcher Mark Beyebach of the Department of Health Sciences of the Public University of Navarre (NUP/UPNA) has conducted a pilot study to demonstrate the positive impact of solution-focused communication by ...
Sep 14, 2018
0
0
The lungs can be a difficult organ to biopsy with a needle, so the promise of identifying lung cancer through a blood-based biopsy has lung cancer experts and patients optimistic. Knowing how and when to use a liquid biopsy ...
Jun 21, 2018
0
3
Whole genome sequencing using long fragment read (LFR), a technology that can analyze the entire genomic content of small numbers of cells, detected potentially targetable mutations using only five circulating tumor cells ...
Aug 15, 2017
0
2
Johnson & Johnson has reached a $33 million settlement with 42 states, resolving allegations the health care giant sold numerous nonprescription medicines that didn't meet federal quality requirements for a couple of years.
May 24, 2017
0
0
